Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

By M. Pfaller, D. Diekema. Clinical Microbiology Reviews, 2007

4,086 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/9d93f3dfee3ac708d0c1fab0179ba84926339b19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Guinea
2. M. Pfaller
3. D. Diekema
4. Mariana Castanheira
5. Ronald N. Jones
6. J. Turnidge
7. M. Nucci
8. T. Walsh

In Infectious Diseases

1. J. Guinea
2. M. Pfaller
3. D. Diekema
4. Mariana Castanheira
5. J. Turnidge
6. Ronald N. Jones
7. M. Nucci
8. Mihai G. Netea

Citations in the corpus

• The Candida Genome Database (CGD): incorporation of Assembly 22, systematic identifiers and visualization of high throughput sequencing data (2016, background): “The frequency of fungal infections has risen dramatically over the past few decades, with the current annual incidence of invasive Candida infections recently estimated to range between 72 and 228 infections per million (3,4).”
• Candida parapsilosis, an Emerging Fungal Pathogen (2008, background): “Since the 1980s, fungi have emerged as major causes of human disease, particularly among immunocompromised individuals and hospitalized patients with serious underlying conditions (210).”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, neutral): “krusei [26, 81], but”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “glabrata [47, 177–179].”
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “In addition to the changing trends in antifungal susceptibility, there has been a recent shift towards more infections in the immunocompromised host being caused by Candida species other than C. albicans [50, 51].”
• Global trends in the distribution of Candida species causing candidemia. (2014, background): “During the last 20 years, we have observed an improvement in diagnostic procedures, the development and commercialization of new antifungal agents, and the implementation of strategies to prevent candidemia; nevertheless, the incidence of candidemia has increased [7].”
• Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes (2012, background): “The observation that C. albicans can prime and enhance the proinflammatory immune response of monocytes may represent a possible reason why C. albicans became a commensal in humans (Pfaller and Diekema, 2007).”
• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “glabrata were most frequently identified in series from Denmark and the United States, although South America had lower rates of these species [31].”
• Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. (2012, background): “With the exception of C. tropicalis, voriconazole is more active than fluconazole against medically important Candida species (Pfaller & Diekema, 2007).”
• Candida albicans pathogenicity mechanisms (2013, background): “Indeed, Candida spp are the fourth most common cause of hospital-acquired systemic infections in the United States with crude mortality rates of up to 50%.(3,4) C.”
• Bacterial-Fungal Interactions: Hyphens between Agricultural, Clinical, Environmental, and Food Microbiologists (2011, background): “Most studies of clinical BFIs to date have focused on Candida albicans (366, 397), a yeast which is common in the buccal, dermal, and intestinal human microbiota but which can also cause a large number of infections (308).”
• Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses (2017, background): “auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
• GENETIC CONTROL OF CANDIDA ALBICANS BIOFILM DEVELOPMENT (2010, neutral): “biofilm development with a focus on Candida albicans , the most frequently isolated Candida pathoge”